Published in Hepatitis Weekly, March 13th, 2006
"Lamivudine was the first approved inhibitor of HBV reverse transcriptase (RT). Lamivudine resistance develops in 53% to 76% of patients after 3 years of treatment," scientists in France report.
"We extensively characterized the dynamics of HBV quasispecies variant populations in four HBV-infected patients who developed lamivudine resistance. Virological breakthrough was preceded by 2 to 4 months by the emergence of quasispecies variants bearing amino acid substitutions at RT position 204, i.e., within the YMDD catalytic motif...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.